Phase 1 MDMA Therapy for Bulimia Nervosa
Summary
The NIH ClinicalTrials.gov registry has registered a new Phase 1 clinical study (NCT07542145) evaluating MDMA Assisted Therapy (MDMA-AT) for Bulimia Nervosa. The 10-week trial will assign participants to MDMA-AT, MDMA-AT-BN, or Standard Treatment groups, with three experimental dosing sessions followed by integrative sessions, 12 psychotherapy sessions, and a 6-month follow-up.
What changed
A new Phase 1 clinical trial registration for MDMA Assisted Therapy (MDMA-AT) has been posted to ClinicalTrials.gov under NIH. The study will examine MDMA-AT as a treatment for Bulimia Nervosa using a three-arm design comparing MDMA-AT, MDMA-AT-BN, and Standard Treatment.
Healthcare providers and clinical researchers treating or studying Bulimia Nervosa should be aware of this investigational study. Clinical trial registrations are informational records and do not create compliance obligations.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
MDMA Assisted Therapy for BN
Phase 1 NCT07542145 Kind: PHASE1 Apr 21, 2026
Abstract
This project will evaluate MDMA Assisted Therapy (MDMA-AT) assisted psychotherapy for the treatment of Bulimia Nervosa (BN) over a 10-week period. Preliminary data suggests that MDMA can facilitate heightened openness and reduce anxiety. This study will determine whether MDMA-assisted therapy can serve as a new treatment for BN. Participants are assigned to one of three groups: MDMA-AT, MDMA-AT-BN, and Standard Treatment (ST). MDMA groups include three experimental session that include dosing, which are each followed by three integrative sessions and also include 12 psychotherapy sessions. A follow-up will take place at 6-months post baseline.
Conditions: Bulimia Nervosa
Interventions: MDMA-AT, MDMA-AT-BN, Standard Treatment (ST)
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.